Comparative Pharmacology
Head-to-head clinical analysis: GASTROMARK versus ULTRAVIST 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROMARK versus ULTRAVIST 300 IN PLASTIC CONTAINER.
GASTROMARK vs ULTRAVIST 300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
None Documented
None Documented
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent